• Group sales revenue +12.6%, order intake +13.4%, underlying EBITDA +15.1%
• Dynamic growth in the Bioprocess Solutions Division; positive trend for the
Lab Products & Services Division
• Sartorius expects significant increases in sales and earnings for 2015 as well.
Fixed dose combinations are desirable for several reasons such as different release profiles and guaranteeing patients´ compliance by reducing the daily intake of a drug product(s).
The BioFlo 320 is truly a step into the future for Eppendorf as a bioprocess equipment manufacturer. New features including autoclavable and single-use vessel flexibility, intelligent sensors, and IP network communication for multi-unit control set it apart as the new premium choice in the bench scale bioprocess market.
As part of its rapidly expanding range of analytical tools for materials characterization, Malvern Instruments will showcase a new chromatography system and detectors at Pittcon 2015 (Mar 8th – 12th, New Orleans, USA). New additions to Malvern’s recently acquired MicroCal microcalorimetry range will also be on display.
The Danish AgriFish agency renews five frame agreements regarding the development, configuration, support and maintenance of Formpipe's grants management solution TAP. The total value of the agreements is estimated to SEK 250 million over a four-year period.
CROMSOURCE, an international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, today announced that it is delivering several modules of a training course on clinical research best practice organised by the SIFC (Italian Cystic Fibrosis Society). The course commenced in December 2014 and will complete in February 2015.
According to LEO Pharma, Ipsen and Grünenthal driving patient-centric leadership has become priority as the patient voice shapes the future for the pharmaceutical industry.
MEGGLE Group Wasserburg was granted an EXCiPACT™ certificate. Auditors from the certifying body SGS (Société Générale de Surveillance, Hamburg, Germany) confirmed in August, 2014 that the MEGGLE Business Group Excipients & Technology complies with the quality standards of Good Manufacturing & Good Distribution Practices (GMP & GDP) for its pharmaceutical excipients.
MEGGLE Business Group Excipients & Technology, one of the world’s leading manufacturers of excipients for the pharmaceuticals industry, will start operating its first US production site in Le Sueur/Minnesota in September 2011. This will eliminate many bureaucratic and customs obstacles for US buyers and strongly accelerate transactions.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.